PHASE-I STUDY OF SYNTHETIC MUC1 PEPTIDES IN BREAST-CANCER (original) (raw)

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

This article is mentioned in:

Abstract

Exposed peptides in the repeat (VNTR) protein core of human mucin 1 (MUC1) could be a target for immunotherapy, as it is highly immunogenic in mice and a human cytotoxic T lymphocytes to MUC1 recognise the peptide. On this basis 13 patients were immunised with a MUC1 peptide - a 20 amino acids dimer conjugated with diphtheria toroid as carrier. In patients with established breast cancer increasing doses (0.15 mg, 0.25 mg, 0.5 mg, 1.0 mg) were used at 2 week intervals (3 injections). No toxicity was found, other than for DTH reaction to the diphtheria carrier; weak antibody and T cell proliferative responses were seen and weak DTH reaction in proportion of patients. The MUC1 peptide appears to be safe but in the form used was not highly immunogenic.

Copy and paste a formatted citation

Spandidos Publications style

XING P, MICHAEL M, APOSTOLOPOULOS V, PRENZOSKA J, MARSHALL C, BISHOP J and MCKENZIE I: PHASE-I STUDY OF SYNTHETIC MUC1 PEPTIDES IN BREAST-CANCER. Int J Oncol 6: 1283-1289, 1995.

APA

XING, P., MICHAEL, M., APOSTOLOPOULOS, V., PRENZOSKA, J., MARSHALL, C., BISHOP, J., & MCKENZIE, I. (1995). PHASE-I STUDY OF SYNTHETIC MUC1 PEPTIDES IN BREAST-CANCER. International Journal of Oncology, 6, 1283-1289. https://doi.org/10.3892/ijo.6.6.1283

MLA

XING, P., MICHAEL, M., APOSTOLOPOULOS, V., PRENZOSKA, J., MARSHALL, C., BISHOP, J., MCKENZIE, I."PHASE-I STUDY OF SYNTHETIC MUC1 PEPTIDES IN BREAST-CANCER". International Journal of Oncology 6.6 (1995): 1283-1289.

Chicago

XING, P., MICHAEL, M., APOSTOLOPOULOS, V., PRENZOSKA, J., MARSHALL, C., BISHOP, J., MCKENZIE, I."PHASE-I STUDY OF SYNTHETIC MUC1 PEPTIDES IN BREAST-CANCER". International Journal of Oncology 6, no. 6 (1995): 1283-1289. https://doi.org/10.3892/ijo.6.6.1283